|Assessment Status||Rapid Review Complete|
|Indication||As monotherapy for the maintenance treatment of adult patients with BRCA-mutated platinum sensitive relapsed ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy. This is a sub-group of the entire licensed population.|
|Rapid review commissioned||23/07/2019|
|Rapid review completed||06/08/2019|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that olaparib not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.